Recent Headlines
Creative Biomart Decides to Pump $300 Million to Strengthen Biosimilar Cell Lines Production
Today on the annual department meeting, Creative BioMart announces that it plans to invest more than $300 million to strengthen its biosimilar cell lines production in global range. The domain sectors of Creative BioMart are recombinant proteins, antibodies and enzymes. Several years ago, the... - November 17, 2013 - Creative Biomart
SFL’s Managing Director to Give Presentation at Informa’s 8th Annual Drug Device Combination Products Event in Berlin
SFL’s Managing Director provides regulatory insight into Drug Device Combination Products in Europe. - November 13, 2013 - SFL Regulatory Affairs & Scientific Communication Ltd
Creative Biomart Announces Commercial Agreement for Services of Biosimilar Cell Lines Manufacturing
Creative Biomart announced today that it has signed a commercial agreement for contract manufacturing pharmaceutical biosimilar cell lines for a big pharma company. - November 10, 2013 - Creative Biomart
VIRUN® & Vital Pharmaceuticals® Expand Operations to Offer a Combined 29 Patents for Raw Material Manufacturing and Finished Product Capabilities
The year 2013 has been a blockbuster renaissance of key partnerships and explosive innovation for VIRUN; early in the year, VIRUN published Chapter 39, Nanotechnology and Nonpolar Active Compounds in Functional Foods through Wiley. In March, Stepan Lipid Nutrition and VIRUN formalized a partnership... - November 05, 2013 - VIRUN
AnaSpec Introduces SensoLyte® 520 TEV (Tobacco Etch Virus) Protease Assay Kit
SensoLyte® 520 TEV (Tobacco Etch Virus) Protease Assay Kit is used for measuring TEV protease quantity and activity. TEV protease is widely used to remove fusion tags from recombinant proteins. - November 01, 2013 - AnaSpec, EGT Group
AveXis-BioLife Launch New Website
AveXis-BioLife is pleased to announce the launch of the company’s brand new website: www.avexisinc.com. The October 2013 unveiling of the website coincides with the company’s licensing of the gene therapy program from The Kaspar Laboratory for the treatment of Spinal Muscular Atrophy... - November 01, 2013 - AveXis Inc.
Empire Genomics and QuaDPharma Join Forces for Cancer Research Fundraiser
Two Buffalo-area CEOs roll up their sleeves to serve the community and give where they live. - October 31, 2013 - Empire Genomics
AveXis-BioLife Licenses Spinal Muscular Atrophy (SMA) Patent Portfolio from Nationwide Children's Hospital and The Ohio State University
BioLife, a synthetic biology platform company soon to be renamed AveXis, has been granted exclusive rights to the spinal muscular atrophy gene therapy program developed at The Research Institute at Nationwide Children’s Hospital and The Ohio State University in Columbus, Ohio. The license... - October 21, 2013 - AveXis Inc.
Creative Biomart Releases New Products in the Middle of Oct.
In the middle of Oct., Creative Biomart releases a new batch a products, including: Ÿ Recombinant Human MUSK, GST-tagged Ÿ Recombinant Human TIRAP, His-tagged Ÿ Native Mouse Hb Ÿ Recombinant Human NCAM2, GST-tagged Ÿ Recombinant Human NBPF15, His-tagged Ÿ Recombinant... - October 19, 2013 - Creative Biomart
Microfluidics Startup NanoCellect Adds Strategic Advisors and Nabs Another $700K from the NIH
NanoCellect, (previously called NanoSort) aims to facilitate breakthrough biomedical discoveries by making cell analysis and sorting technology more affordable and easier to use. Spunout from UCSD in late 2009, NanoCellect has now raised over $3.3M including a new $700K grant to continue developing... - October 19, 2013 - NanoCellect
AveXis BioLife Announce The Research Institute at Nationwide Children’s Hospital Received Fast Track Status for Spinal Muscular Atrophy Treatment
AveXis and BioLife, synthetic biology platform companies, today announced that The Research Institute at Nationwide Children’s Hospital received Fast Track designation from the U.S. Food and Drug Administration for its scAAV9.CB.SMN gene therapy product for the treatment of spinal muscular... - October 18, 2013 - AveXis Inc.
Mini-Gastric Bypass Performed with SPIDER® Surgical System
Internationally respected surgeon Dr. Michel Gagner completed procedure using fewer incisions. - October 10, 2013 - TransEnterix
MD Stem Cells Indicates Government Shutdown Will Not Impact SCOTS Eye Stem Cell Treatment Study
MD Stem Cells sees no immediate effect on the SCOTS eye stem cell trial but is monitoring NIH throughout the government shutdown. - October 03, 2013 - MD Stem Cells
HALDEY Pharmaceutical Compounding President to Address Brooklyn Physicians on Oct. 2
Dr. Emil J. Haldey will speak before an audience of doctors at the Medical Society of the County of Kings, in association with the Academy of Medicine of Brooklyn. - October 01, 2013 - HALDEY Pharmaceutical Compounding
The Changing Environment for Pharma and Medtech Companies in Europe
SFL Regulatory Affairs Consulting Ltd. (SFL) is pleased to be strengthening its activities in the UK and will be holding an inaugural and networking event in London on 8 October 2013. - September 30, 2013 - SFL Regulatory Affairs & Scientific Communication Ltd
Creative Biomart is Going to Sign Luciferase Supply Agreement with Kasain Laboratory
After a long-term contact and discussion, Creative Biomart finally agrees to sign a Luciferase supply agreement with Kasain Laboratory, especially Native Vibrio fischeri Luciferase (http://www.creativebiomart.net/description_390631_24.htm) until Kasain finishes its study projects. The official... - September 22, 2013 - Creative Biomart
SignaBlok Achieves Key in Vivo Proof of Concept for Treatment of Cancer and Sepsis
Novel First-in-Class Peptide Inhibitor of TREM-1 Modulates the Inflammatory Response and Shows Promise for Treatment of Cancer and Sepsis - September 18, 2013 - SignaBlok, Inc.
AveXis Inc. Names Director, Scientific and Corporate Affairs
AveXis Inc. (avexisinc.com), a synthetic biology platform company, today announced Mindy Du as the company’s new Director of Scientific and Corporate Affairs. This is an essential position within the company, as AveXis is focused on research/development of leading-edge technology for disease... - September 13, 2013 - AveXis Inc.
NIH Awards Advaita $2.0M for Disease Subtyping and Drug Repurposing Technology Development
The National Institute of General Medical Sciences of the National Institutes of Health issued a Notice of Award granting a Fast-Track Small Business Investigational Research (SBIR) Phase I and Phase II grant of $2.0 million for Advaita Bioinformatics, of Plymouth, Michigan to develop biological... - September 13, 2013 - Advaita
Silicon Kinetics® Ramps Commercial Efforts for Affinity Capture-Mass-Spectrometry (AC-MS)
Appoints Jay Smith as CEO and Keith Waddell as VP Business Development - September 12, 2013 - Silicon Kinetics
SafeStitch Medical Completes Merger with TransEnterix
$30 Million Financing Raised from Existing TransEnterix and SafeStitch Medical Stockholders, Combined Company to be Renamed TransEnterix. - September 06, 2013 - TransEnterix
SFL’s Managing Director Invited to Share Expertise at “Pharma Meets Medtech” Event
SFL's Managing Director offers insights for better pharm and medtech collaboration - September 01, 2013 - SFL Regulatory Affairs & Scientific Communication Ltd
CHI Interviews Janet L. Lathey, Ph.D of Emergent BioSolutions on Optimizing Bioassays for Biologics
Janet L. Lathey, Ph.D., Director, Immunology and Assay Development, BioDefense Division, Emergent BioSolutions sits down with conference producer Samantha Lewis to discuss the biggest challenges to managing bioassay variability, new tools and strategies that researchers are using to combat it, and... - August 26, 2013 - Cambridge Healthtech Institute
Creative Biomart Launches Controlled Randomization Service for Random Nucleotide Substitutions
The GenePowerTM Controlled Randomization technology allows you to accurately direct the effective frequency of random nucleotide substitutions. And unlike error-prone PCR, you decide exactly which part(s) of the gene are affected—randomize the entire open reading frame or confine the mutagenesis to specific regions. - August 24, 2013 - Creative Biomart
AveXis Inc. Names Director of Clinical Operations and Research
AveXis Inc. (avexisinc.com), a synthetic biology platform company, today announced Minna Du as the company’s Director of Clinical Operations and Research. This is a critical position within the company, as AveXis is focused on research/development of technology for disease treatment. - August 21, 2013 - AveXis Inc.
Creative Biomart Releases New Antibody Products—Nanobodies
Creative Biomart releases new antibody products, nanobodies, recently. Compared to conventional antibodies, nanobodies also integrate the features of small molecules. - August 18, 2013 - Creative Biomart
MoBiTec GmbH, Germany, is Offering SURE Gene Expression System for Bacillus Subtilis, Regulated by Subtilin
A system for SUbtilin-Regulated gene Expression (SURE) in Bacillus subtilis is offered. Subtilin is a small peptide antibiotic produced by Bacillus subtilis. The SURE system provides an alternative to, e.g., IPTG or xylose inducible systems. - August 17, 2013 - MoBiTec GmbH
Cheers: Researchers Identified New Brain Markers with Creative Biomart’s S100B Antibody
In the study, researchers used the critical products purchased from Creative Biomart. During the process, the serum levels of molecular markers were determined by ELISA using antibodies and antigens from Creative Biomart (New York, NY) (S100B) which you can see in the article. - August 16, 2013 - Creative Biomart
Experts from Creative Biomart Share the Experience on Using Elisa Kits to Improve the Precision of an Assay
There are some issues that researchers might meet in the process of using ELISA Kits. In order to help improve the precision of an assay, Creative Biomart (http://www.creativebiomart.net/) experts concluded the following tips for reference. - August 14, 2013 - Creative Biomart
Research Antibody Survey: Creative Biomart Conducted a Survey Among Antibodies Users
In order to direct market and perfect products, Creative Biomart conducted the survey. And the survey results are listed as follows. - August 03, 2013 - Creative Biomart
AveXis Inc. Names Chief Scientific Officer
AveXis Inc. (avexisinc.com), a synthetic biology platform company focused on research and development of technology for disease treatment, today announced Dr. Allan A. Kaspar will serve as the company’s first Chief Scientific Officer (CSO). Dr. Kaspar has held research positions at multiple... - August 01, 2013 - AveXis Inc.
New Company Formed to Focus on New Technology for Disease Treatment
AveXis Inc. (avexisinc.com) announced its formation as a company focused on research and development of technology specifically for disease treatment. A synthetic biology platform company, AveXis has, at its core, a desire to establish unique industry alliances which will bring innovative... - July 27, 2013 - AveXis Inc.
Final Agenda Announced for CHI’s FAST: Functional Analysis & Screening Technologies Congress
Headlined by Karen Burg, DL Taylor, Steve Ludbrook and Aaron Morris, CHI's FAST Congress features three days of innovative presentations for more accurate biological response in drug discovery through novel screening technologies and strategies. - July 27, 2013 - Cambridge Healthtech Institute
New Research Validates Importance of Central Lab to Overall Investigator Satisfaction
More than 250 Clinical Investigators Indicate Central Lab Preference - July 26, 2013 - Life Science Strategy Group, LLC
OsoBio Appoints Lindsey Pruitt to Manage East Coast Business Development Efforts
Working in her new capacity in OsoBio’s Philadelphia location, Pruitt will identify and foster new business opportunities throughout the Northeast. - July 22, 2013 - OSO BioPharmaceuticals Manufacturing, LLC
Four Insightful Conferences to be Held at CHI's Fifth Annual Immunogenicity Summit 2013
Technologies and Strategies for Safe and Efficacious Products in the Clinic - July 15, 2013 - Cambridge Healthtech Institute
Creative Biomart Launched Novel Animal-free Recombinant Proteins for Stable Research
The novel animal-free protein production system is more efficient, fast, flexible and cheap compared to transgenic plants recombinant proteins production; the scaling-up compared with bio-reactors is simple and lineal. It doesn't have issues with inclusion bodies as E.coli. - June 28, 2013 - Creative Biomart
F2G Ltd and the University of Manchester Announce a New 6.1 Million Euro Project to Develop New Antifungal Agents to Treat Resistant Fungal Infections.
F2G Ltd, a privately-held antifungal drug discovery and development company and The University of Manchester, today announced the commencement of a 6.1 million euro EU-funded project to discover and develop novel antifungal drugs to treat serious, life-threatening fungal infections. The NOFUN... - June 28, 2013 - F2G Ltd
OsoBio Names Kathleen Larese Director of Laboratories
OsoBio has named Kathleen Larese director of laboratories. As part of OsoBio’s quality control department, the microbiology and chemistry laboratories that Larese now directs are responsible for environmental monitoring, analytical method development, and testing all incoming raw materials,... - June 26, 2013 - OSO BioPharmaceuticals Manufacturing, LLC
TransEnterix Develops Patient-Side Robotic Surgical Platform
Company's single-site mobile robot is now undergoing pre-clinical testing. - June 26, 2013 - TransEnterix
MD Stem Cells Shows Retinal Eye Disease Responds to Stem Cells with Significant Vision Improvement
Blinding retinal eye disease called Retinitis Pigmentosa seen to make major gains in visual acuity following adult stem cell therapy in the United States. - June 20, 2013 - MD Stem Cells
NanCogenics Reports Research Findings on Tumor-Localization of Cancer Therapeutics
Research results on the use of magnetic nanovectors for the tumor-specific localization of cancer therapeutics is discussed. - June 08, 2013 - NanCogenics Inc
CovalX and Bruker Daltonics Announce Strategic Collaboration in High Mass MALDI Detection
Joint Support of CovalX High Mass Detection Systems for all Bruker autoflex and ultraflex series instruments worldwide will provide new and existing Bruker MALDI customers with access to CovalX applications for protein interaction and macromolecular analysis. - June 07, 2013 - CovalX
MoBiTec GmbH and Bachem Americas, Inc., Sign Distribution Agreement for the European Market
MoBiTec GmbH, a Germany based biotech company focused on products for life science research, has entered into a distribution agreement with Bachem Americas, Inc., USA. Together with Bachem Americas, MoBiTec will continue to expand its portfolio of premier brands and high-quality products through the addition of Bachem’s high-quality immunology products. - June 01, 2013 - MoBiTec GmbH
Creative Biomart Scientists Found That Shutdown Gene Arih2 May Treat Hepatitis
Arih2 was found within the sentinel dendritic cells of the immune system, which play a vital role in defending intruders. - May 31, 2013 - Creative Biomart
Tucson Surgeon First in State to Offer SPIDER Gastric Sleeve for Weight Loss
Dr. Patrick Chiasson at Southern Arizona Center for Minimally Invasive Surgery also uses novel single-incision surgical platform for gallbladder removal. - May 30, 2013 - TransEnterix
Coral Products Launch Kitchen Caddy with SteriTouch®
Merseyside-based Coral Products plc has introduced an antimicrobial food recycling bin to its range of products supplied to local authorities, and is confident that this development will encourage the use of food caddies in the home. Incorporating SteriTouch® universal masterbatch into the... - May 30, 2013 - SteriTouch Ltd
MiTeGen Announces Collaboration and License Agreements with EMBL
MiTeGen LLC, a provider of innovative consumables for X-ray diffraction, crystallography and protein crystallization to academic, pharmaceutical, industrial and government researchers around the world, announced that it has signed agreements with EMBLEM, the commercial subsidiary of the EMBL (the... - May 23, 2013 - MiTeGen, LLC
Md Stem Cells Continues Billion Cell Treatments for Eye Disease
MD Stem Cells Reports Billion Cell Harvests for Eye Stem Cell Treatments in Florida. - May 11, 2013 - MD Stem Cells
Creative BioMart Funded Research Found Another Anticancer Strategy - Targeting Cyclin D
Researchers successfully silenced abnormal proteins that control cells' growth cycle. - May 10, 2013 - Creative Biomart